Fundraising Fox
/Companies
Sign in

AOBiome

Cambridge, US · Founded 2012 · 18 employees on LinkedIn · 2 known investors

Find your way into AOBiome

Sign up to see every warm intro you have to AOBiome

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the AOBiome team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

AOBiome Therapeutics is a late-stage biotechnology company developing microbiome-based treatments for inflammatory skin conditions such as atopic dermatitis and pruritus. Its lead candidate, B244, uses a single strain of Ammonia Oxidizing Bacteria to moderate immune response by simultaneously down-regulating multiple inflammatory markers (IL-4, IL-5, IL-13, IL-31).

BiotechDigital HealthHealthtechWellness & Fitness

Founders & leadership

AOBiome was founded in 2012 by Jamie Heywood.

JHJamie Heywood
Jamie HeywoodCo-Founder & Board Member, Former CEO and ChairmanJamie Heywood studied mechanical engineering at MIT and has worked on drug discovery through ALS TDI, co-founded PatientsLikeMe, and currently holds a role at Alden Scientific involving proteomics and machine learning research.
SJ
Spiros JamasFounding CEO2013–2021Spiros Jamas holds a Doctor of Science in Biotechnology from MIT and has held CEO or founder roles at multiple biopharmaceutical companies including Entera Bio, Tempero Pharmaceuticals, Enanta Pharmaceuticals, and Alpha-Beta Technology, with prior experience as a healthcare analyst at State Street Global Advisors.
TKTodd Krueger
Todd KruegerChief Executive Officer, President and Director

Board

LB
Leonard BarshackManager of Issuer
WT
Walter ThompsonManager of Issuer

Investors · 2

Also in the syndicate · 1

iCarbonX

Reported raises · per SEC filings

Form D private placements

$3.1M disclosed across 2 of 3 rounds · 2014–2017

▶$2.5MraisedSep 2015 · 2 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Leonard BarshackDirector
  • Spiros JamasExecutive Officer, Director
  • James HeywoodDirector
  • Walter ThompsonDirector
Offering amount
$15M
Amount sold
$2.5M
First sale
Sep 2015
Incorporated
Limited Liability Company, Delaware, 2012
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$576.5KraisedAug 2014 · 13 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • James HeywoodExecutive Officer, Director
  • Spiros JamasExecutive Officer
  • Walter G. ThompsonDirector
  • Leonard BarshackDirector
Offering amount
$7.5M
Amount sold
$576.5K
First sale
Aug 2014
Incorporated
Limited Liability Company, Delaware, 2012
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Founder mafia

4 people who came through AOBiome went on to found or lead other companies.

Jamie HeywoodCo-founderFounded geneticnetworks +1Klaus DugiNon Executive DirectorFounded VandriaJasmina AganovicGeneral Manager of Consumer ProductsFounded ArcaeaElsa JungmanProduct ManagerFounded HelloBiome

Related companies · 1

Mission BioCapital Platinum Program Holdings LLCMission BioCapital is a venture capital firm that invests in early-stage life science companies, from therapeutics and drug discovery to biotech tools and diagnostics. The firm provides capital, operational support, and lab infrastructure through its MBC BioLabs co-working spaces to help scientific entrepreneurs launch and scale biotech startups.

Companies working in the same space as AOBiome.

In the news

AOBiome Partners with iCarbonX and Secures $30 Million Investment for Drug Development - AOBiomeaobiome.com · Jan 2017

Frequently asked questions

What does AOBiome do?
AOBiome Therapeutics is a late-stage biotechnology company developing microbiome-based treatments for inflammatory skin conditions such as atopic dermatitis and pruritus. Its lead candidate, B244, uses a single strain of Ammonia Oxidizing Bacteria to moderate immune response by simultaneously down-regulating multiple inflammatory markers (IL-4, IL-5, IL-13, IL-31).
Who founded AOBiome?
AOBiome was founded by Jamie Heywood in 2012.
Who are AOBiome's investors?
AOBiome's investors include Wakestream Ventures.
How much funding has AOBiome raised?
AOBiome has disclosed $3.1M raised across 2 of its 3 known rounds.
Where is AOBiome headquartered?
AOBiome is headquartered in Cambridge, US.